A biotechnology pioneer company in developing a novel class of drugs based on Nanoparticle delivery to treat Cancer and Neurological Diseases.

Onselex develops new drugs built upon nanoparticle encapsulation advanced technology to treat cancer and neurological diseases.

Targeted administration of certain oncology medications based on the nanoparticle technology will reduce adverse reactions arising from the toxicity of oncology medications by more than 95 percent—compared to typical standard chemotherapy treatments—thereby significantly reducing cancer patients' suffering and effectively increasing the likelihood of complete recovery.

Onselex provides a foundation for the development of powerful drugs that selectively target cancer cells, and plans to expand its platform to include other areas of treatments. The new drug and professional development areas of Onselex include cell and molecular biology, biochemistry, structural biology, chemistry, virology, pathology, and pharmacology. Onselex is also in partnership with scientists, laboratories, and major pharmaceutical companies of worldwide renown.

Onselex will continue to invest in technologies to develop next-generation new drugs, focus on technological development, and proudly establish itself as a leader paving the way for the development of next-generation new biological drugs, thus promoting and protecting human health.

Thank you very much for your support and considerations.

CEO Ernest Shin